Literature DB >> 1885063

Natural history of gastro-oesophageal reflux disease without oesophagitis.

F Pace1, F Santalucia, G Bianchi Porro.   

Abstract

This retrospective study was undertaken to characterise the clinical course and reflux pattern of patients with gastro-oesophageal reflux without evidence of oesophagitis. We investigated 33 patients (12 women, 21 men; mean age 36 years) with typical symptoms, a negative oesophagoscopy, and a 24 hour oesophageal pH-metry indicative of pathological gastro-oesophageal reflux. All patients received antacids or prokinetic drugs or both for three to six months. Nineteen of 33 patients still had symptoms at the end of treatment, of whom five had developed erosive changes of the oesophageal mucosa. The other 14 discontinued treatment and remained asymptomatic during a six month follow up period. Comparison of the pretreatment pH-metry data of the 19 symptomatic patients and the 14 asymptomatic patients showed no differences in the pattern of gastro-oesophageal reflux in the two groups. We conclude that in a substantial proportion of patients with pathological reflux without oesophagitis symptoms may persist and mucosal lesions may develop during conventional treatment without any apparent change in the reflux. Patients who developed endoscopic oesophagitis did not have a more severe pretreatment pattern of gastro-oesophageal reflux when compared with those who did not develop oesophageal mucosal damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885063      PMCID: PMC1378949          DOI: 10.1136/gut.32.8.845

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Medical therapy for chronic reflux esophagitis. Long-term follow-up.

Authors:  D A Lieberman
Journal:  Arch Intern Med       Date:  1987-10

2.  Medical and surgical management of reflux esophagitis. A 38-month report of a prospective clinical trial.

Authors:  J Behar; D G Sheahan; P Biancani; H M Spiro; E H Storer
Journal:  N Engl J Med       Date:  1975-08-07       Impact factor: 91.245

3.  Epidemiology of oesophageal reflux disease.

Authors:  R C Heading
Journal:  Scand J Gastroenterol Suppl       Date:  1989

4.  Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis.

Authors:  F Pace; O Sangaletti; G Bianchi Porro
Journal:  Ital J Gastroenterol       Date:  1990-02

Review 5.  Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy.

Authors:  J E Richter; D O Castell
Journal:  Ann Intern Med       Date:  1982-07       Impact factor: 25.391

6.  Healing and relapse of reflux esophagitis during treatment with ranitidine.

Authors:  H R Koelz; R Birchler; A Bretholz; B Bron; Y Capitaine; G Delmore; H F Fehr; I Fumagalli; J Gehrig; J J Gonvers
Journal:  Gastroenterology       Date:  1986-11       Impact factor: 22.682

7.  Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux.

Authors:  G J Maddern; G K Kiroff; P I Leppard; G G Jamieson
Journal:  J Clin Gastroenterol       Date:  1986-04       Impact factor: 3.062

8.  Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease.

Authors:  N E Schindlbeck; C Heinrich; A König; A Dendorfer; F Pace; S A Müller-Lissner
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

9.  Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists.

Authors:  G Bianchi Porro; F Pace; O Sangaletti
Journal:  Scand J Gastroenterol       Date:  1990-08       Impact factor: 2.423

  9 in total
  23 in total

Review 1.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  Functional Gastroesophageal Reflux Disease (GERD).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

Review 3.  Heterogeneity of endoscopy negative heartburn: epidemiology and natural history.

Authors:  Fabio Pace; Valentina Casini; Stefano Pallotta
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

4.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: pro.

Authors:  Tomás Navarro-Rodriguez; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

5.  [Antireflux therapy--more than acid reduction?].

Authors:  T Frieling
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

6.  Bleeding and stenosis caused by reflux esophagitis was not common in emergency endoscopic examinations: a retrospective patient chart review at a single institution in Japan.

Authors:  Miyuki Yamaguchi; Ryuichi Iwakiri; Kanako Yamaguchi; Toshihiko Mizuta; Ryo Shimoda; Yasuhisa Sakata; Akitaka Hisatomi; Masanobu Mizuguchi; Seiji Sato; Kohji Miyazaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

7.  Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure.

Authors:  Fabio Pace; Stefano Pallotta; Gianpiero Manes; Annalisa de Leone; Patrizia Zentilin; Luigi Russo; Vincenzo Savarino; Matteo Neri; Enzo Grossi; Rosario Cuomo
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

8.  Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients.

Authors:  E Kuster; E Ros; V Toledo-Pimentel; A Pujol; J M Bordas; L Grande; C Pera
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 9.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

10.  Nonerosive Reflux Disease (NERD) - An Update.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.